OOIR: Observatory of International Research

Papers

(The TQCC of Expert Opinion on Investigational Drugs is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)

Article	Citations
Navafenterol for chronic obstructive pulmonary disease therapy	92
Do histone deacytelase inhibitors and azacitidine combination hold potential as an effective treatment for high/very-high risk myelodysplastic syndromes?	85
Experimental drugs for supraventricular tachycardia: an analysis of early phase clinical trials	80
Novel experimental and early investigational drugs for the treatment of bipolar disorder	78
JAK inhibitors for rheumatoid arthritis	75
Tucatinib: an investigational novel therapeutic agent for the treatment of HER-2 colorectal cancer	69
Immune-based combinations for metastatic triple negative breast cancer in clinical trials: current knowledge and therapeutic prospects	69
Lipid metabolism and the targeting of angiopoietin-like 3: Experimental drugs under development	64
Investigational drugs for HIV: trends, opportunities and key players	58
Immunotherapy for triple negative breast cancer: How can pathologic responses to experimental drugs in early-stage disease be enhanced?	51
Investigational immunotherapy targeting CD19 for the treatment of acute lymphoblastic leukemia	48
Targeting leukemia inhibitory factor in pancreatic adenocarcinoma	42
The effect of a single escalating dose of long-acting recombinant human follicle-stimulating hormone Fc fusion protein (KN015) on healthy, pituitary-suppressed women: first-in-human and randomized stu	41
Ulcerative colitis: shedding light on emerging agents and strategies in preclinical and early clinical development	41
A randomized, double-blind, placebo-controlled, single, and multiple dose-escalation Phase I clinical trial to investigate the safety, pharmacokinetic, and pharmacodynamic profiles of oral S086, a nov	39
Therapeutic challenges at the preclinical level for targeted drug development for Opisthorchis viverrini-associated cholangiocarcinoma	34
The treatment of advanced melanoma: a review of systemic and local therapies in combination with immune checkpoint inhibitors in phase 1 and 2 clinical trials	33
Progress in the treatment of anal cancer: an overview of the latest investigational drugs	32
Odevixibat: an investigational inhibitor of the ileal bile acid transporter (IBAT) for the treatment of biliary atresia	32
Therapies in preclinical and in early clinical development for the treatment of urinary tract infections: from pathogens to therapies	31
Epidermal growth factor receptor antagonists in colorectal cancer: emerging strategies for precision therapy	30
New investigational drugs to treat Sjogren's syndrome: lessons learnt from immunology	29
From bench to bedside - is there a role of IL-17 drugs in rheumatoid arthritis?	29
A phase I, randomized, double-blind, single-dose pharmacokinetic study to evaluate the biosimilarity of SB16 (proposed denosumab biosimilar) with reference denosumab in healthy male subjects	28
Bomedemstat as an investigative treatment for myeloproliferative neoplasms	26

Experimental autotaxin inhibitors for the treatment of idiopathic pulmonary fibrosis	24
Novel preclinical developments of the primary sclerosing cholangitis treatment landscape	24
Lessons learned from early-stage clinical trials for diabetic nephropathy	23
Investigational follicle-stimulating hormone receptor agonists for male infertility therapy	22
Dipeptidyl peptidase 4-inhibitor treatment was associated with a reduced incidence of neoplasm in patients with type 2 diabetes: a meta-analysis of 115 randomized controlled trials with 121961 partici	21
Current and emerging investigational venetoclax-based therapies in chronic lymphocytic leukemia	21
Bruton tyrosine kinase inhibitors: can they be optimized for the treatment of neuroinflammatory disorders?	20
The triple negative breast cancer drugs graveyard: a review of failed clinical trials 2017-2022	20
Ongoing and evolving clinical trials enhancing future colorectal cancer treatment strategies	20
Investigational immunomodulatory drugs for enhancement of triple negative breast cancer (TNBC) immunotherapy: early phase development	19
Experimental drugs in clinical trials for acute myeloid leukemia: innovations, trends, and opportunities	18
An evaluation of KBP-5074 in advanced chronic kidney disease with uncontrolled hypertension	18
SGLT2 inhibitors: an evidence-based update on cardiovascular implications	18
Targeted therapies for gallbladder cancer: an overview of agents in preclinical and clinical development	17
Theranostic strategies in sarcoma: preliminary clinical evidence	17
Investigational drugs for the treatment of olfactory dysfunction	17
AXS-05: an investigational treatment for Alzheimer’s disease-associated agitation	17
Investigational agents for autosomal dominant polycystic kidney disease: preclinical and early phase study insights	17
Druggable molecular alterations in bile duct cancer: potential and current therapeutic applications in clinical trials	16
Fibroblast growth factor therapies in biliary tract cancers: current and future state	16
MK-6482 as a potential treatment for von Hippel-Lindau disease-associated clear cell renal cell carcinoma	15
Therapeutic interventions for spinal muscular atrophy: preclinical and early clinical development opportunities	15
RNAi therapeutics for diseases involving protein aggregation: fazirsiran for alpha-1 antitrypsin deficiency-associated liver disease	15
Emerging treatment landscape for Guillain-Barré Syndrome (GBS): what’s new?	14
Emerging pharmacotherapies for the treatment of pulmonary arterial hypertension	14
Litifilimab (BIIB059), a promising investigational drug for cutaneous lupus erythematosus	14
Inhibition of KIT for chronic urticaria: a status update on drugs in early clinical development	14
First-in-human trial of SAR107375E, a novel small molecule anticoagulant with dual inhibition of factor Xa and factor IIa	14
Experimental drugs for the prevention or treatment of sensorineural hearing loss	13
New investigational drugs for steroid-refractory acute graft-versus-host disease: a review of the literature	13
Recent progress in tyrosine kinase 2 inhibitors for atopic dermatitis	13
Investigational and emerging gastric inhibitory polypeptide (GIP) receptor-based therapies for the treatment of obesity	13
Experimental drugs in randomized controlled trials for long-COVID: what’s in the pipeline? A systematic and critical review	13
Application of engineered antibodies (scFvs and nanobodies) targeting pathological protein aggregates in Alzheimer’s disease	13
Key challenges for drugs in clinical development for cholangiocarcinoma	12
Therapeutic potential of cannabidiol (CBD) in the treatment of cardiovascular diseases	12
Breakthrough therapy designation of nirsevimab for the prevention of lower respiratory tract illness caused by respiratory syncytial virus infections (RSV)	12
Therapies in preclinical and clinical development for Angelman syndrome	12
Investigational CXCR4 inhibitors in early phase development for the treatment of hematological malignancies	12
Investigational spleen tyrosine kinase (SYK) inhibitors for the treatment of autoimmune diseases	12
Bioavailability and pharmacokinetic profile of balovaptan, a selective, brain-penetrant vasopressin 1a receptor antagonist, in healthy volunteers	11
Targeted therapies for extrahepatic cholangiocarcinoma: preclinical and clinical development and prospects for the clinic	11
Investigational drugs for ischemic stroke: what’s in the clinical development pipeline for acute phase and prevention?	11
Low-dose aspirin for early COVID-19: does the early bird catch the worm?	11
Anti-diabetic drugs and NASH: from current options to promising perspectives	11
Potential experimental immune checkpoint inhibitors for the treatment of cancer of the liver	11
Emerging drugs for the treatment of radioactive iodine refractory papillary thyroid cancer	10
Investigational bispecific antibodies for the treatment of rheumatoid arthritis	10
Interleukin antagonists for atopic dermatitis: a new era of therapy	10
Combination therapies in clinical trials for renal cell carcinoma: how could they impact future treatments?	10

Deterministic reprogramming and signaling activation following targeted therapy in non-small cell lung cancer driven by mutations or oncogenic fusions	10
Targeting diarrhea-predominant irritable bowel syndrome: hopes or hypes?	10
The role of phosphodiesterase 9A inhibitors in heart failure	10
Foreword: hepatocellular carcinoma: emerging treatments, drug targets, and fundamental knowledge gaps	10
The role of extracellular vesicles in immune cell exhaustion and resistance to immunotherapy	10
Taletrectinib for the treatment of ROS-1 positive non-small cell lung cancer: a drug evaluation of phase I and II data	10
Novel JAK inhibitors under investigation for systemic lupus erythematosus: - where are we now?	10
Ladiratuzumab vedotin for metastatic triple negative cancer: preliminary results, key challenges, and clinical potential	9
Investigational drugs for the treatment of scleroderma: what’s new?	9
‘Why is survival with triple negative breast cancer so low? insights and talking points from preclinical and clinical research’	9
Investigational treatment strategies in glioblastoma: progress made and barriers to success	9
Tilsotolimod: an investigational synthetic toll-like receptor 9 (TLR9) agonist for the treatment of refractory solid tumors and melanoma	9
Psoriasis: a focus on upcoming oral formulations	9
Investigational topical anticholinergics in clinical development for the treatment of hyperhidrosis	9
T-cell acute lymphoblastic leukemia: promising experimental drugs in clinical development	9
Atezolizumab: an investigational agent for the treatment of biliary tract cancer	9
Emerging neuroprotective interventions in periventricular leukomalacia - A systematic review of preclinical studies	9
Experimental drugs for fallopian cancer: promising agents in the clinical trials and key stumbling blocks for researchers	9
Drugs in phase I and II clinical development for the prevention of stroke in patients with atrial fibrillation	8
Ulotaront: a TAAR1/5-HT1A agonist in clinical development for the treatment of schizophrenia	8
A randomized, adaptive design, double-blind, 3-arm, parallel study assessing the pharmacokinetics and safety of AVT02, a high-concentration (100 mg/mL) Adalimumab biosimilar, in healthy adult subjects	8
Collocation of metformin and dipeptidyl peptidase-4 inhibitor is associated with increased risk of diabetes-related vascular dementia: A single hospital study in Northern Taiwan	8
Targeting Ebola virus replication through pharmaceutical intervention	8
Correction	8
JAK inhibitors in crohn’s disease: ready to go?	8
Investigational drugs in clinical trials for macular degeneration	8
Single and multiple dose pharmacokinetics and safety of ZSP1273, an RNA polymerase PB2 protein inhibitor of the influenza A virus: a phase 1 double-blind study in healthy subjects	8
Hepatitis D virus (HDV): investigational therapeutic agents in clinical trials	8
Clinical development of passive tau-based immunotherapeutics for treating primary and secondary tauopathies	7
The first-in-human study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of the factor XI monoclonal antibody SHR-2004 in healthy subjects	7
Retatrutide: a triple incretin receptor agonist for obesity management	7
Elinzanetant: a phase III therapy for postmenopausal patients with vasomotor symptoms	7
Zilucoplan: An Investigational Complement C5 Inhibitor for the Treatment of Acetylcholine Receptor Autoantibody–Positive Generalized Myasthenia Gravis	7
Experimental drugs in clinical trials for COPD: artificial intelligence via machine learning approach to predict the successful advance from early-stage development to approval	7
Developments and challenges for new and emergent preparations for male hypogonadism treatment	7
Experimental drugs for the treatment of idiopathic intracranial hypertension (IIH): shedding light on phase I and II trials	7
Experimental drugs for erosive esophagitis: what is in the clinical development pipeline?	7
Developing targeted therapeutics for hepatocellular carcinoma: a critical assessment of promising phase II agents	7
Experimental drugs for Friedrich’s ataxia: progress and setbacks in clinical trials	7